Daily Weight Loss Newsletter

Subject: GLP-1 shake-up, weight regain science, and what actually helps you keep the weight off
Preview text: Today’s evidence says sustainable progress is less about perfection—and more about the systems that make results stick.

1) Today’s News Headlines

The biggest weight-loss story right now is not a miracle diet—it’s access, safety, and maintenance. The FDA said in February it will take action against non-FDA-approved compounded GLP-1 drugs being marketed as alternatives to approved medications, underscoring how fast the market is changing and how important it is to stick with regulated, prescribed treatments. (fda.gov)

At the same time, new research is reinforcing a truth many dieters learn the hard way: weight loss is only half the battle; keeping it off is where the real challenge begins. A recent systematic review found lifestyle interventions ranked highest for preventing recurrent weight gain, while semaglutide helped maintain loss during ongoing use but was followed by rebound after discontinuation. (pubmed.ncbi.nlm.nih.gov)

2) Today’s Top Stories

Headline: FDA warns against unapproved compounded GLP-1 products

The FDA announced on February 6, 2026, that it intends to restrict GLP-1 active ingredients used in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to approved medications. The agency says it cannot verify the quality, safety, or efficacy of those products and also warned against misleading claims that compounded versions are generic or clinically proven replacements. (fda.gov)

Why it matters: If you’re using a GLP-1, the safest path is a regulated, prescribed product with medical oversight.

Source: fda.gov

Headline: New review says maintenance needs more than medication alone

A 2026 systematic review of randomized controlled trials found that lifestyle interventions ranked highest for preventing recurrent weight gain after weight loss, while semaglutide appeared helpful for maintaining reductions only while treatment continued. The authors also found rebound after discontinuation, which is a reminder that obesity treatment is usually chronic care, not a one-time event. (pubmed.ncbi.nlm.nih.gov)

Why it matters: Readers should think in terms of long-term strategy, not “finish line” dieting.

Source: pubmed.ncbi.nlm.nih.gov

Headline: Real-world obesity clinics are showing longer-term success when support continues

A recent real-world telehealth obesity clinic study reported continued weight loss between 18 and 24 months among people using anti-obesity medications, suggesting that ongoing engagement and structured follow-up may help patients keep progressing over time. This is observational data, so it can’t prove causation—but it does point to the value of accountability, coaching, and continuity of care. (pubmed.ncbi.nlm.nih.gov)

Why it matters: Systems and support often matter as much as the treatment itself.

Source: pubmed.ncbi.nlm.nih.gov

Headline: GLP-1 pricing pressure may improve access, but affordability is still uneven

STAT reported in late February that Novo Nordisk and Lilly have been cutting net prices for popular GLP-1 weight-loss drugs through discounts to insurers and consumers, including deals tied to the Trump administration. Even if list prices stay high, lower net pricing could eventually affect coverage decisions and out-of-pocket costs for some patients. (statnews.com)

Why it matters: Access is improving for some, but affordability remains a major barrier for many people.

Source: statnews.com

3) Deep Dive Section — Tuesday: Science Simplified

Why weight comes back: the biology behind “I did everything right”

A lot of people assume weight regain means they failed. The science says otherwise. In the new review, lifestyle treatment was best at preventing recurrent gain, but medication help like semaglutide worked best while treatment continued—supporting the idea that weight regulation is biologically defended, not just a matter of willpower. (pubmed.ncbi.nlm.nih.gov)

Here’s the practical takeaway: if your plan is only “eat less for a while,” your body may eventually push back through hunger, cravings, and lower energy expenditure. That doesn’t mean sustainable change is impossible—it means the solution should include repeatable habits: higher-protein meals, regular movement, sleep, stress management, and realistic calorie targets you can live with long term. The review also strengthens a common myth-bust: “If you regain weight, the method was a scam” is not supported by the evidence; often the method simply wasn’t designed for maintenance. (pubmed.ncbi.nlm.nih.gov)

Bottom line: Whether you use lifestyle tools, medication, or both, the goal is to build a system that still works on your busiest, hardest week—not just your most motivated one. (pubmed.ncbi.nlm.nih.gov)

4) Quick Hits

• FDA safety messaging around compounded GLP-1s is likely to keep shaping pharmacy access and telehealth prescribing. (fda.gov)
• Zepbound remains FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, alongside diet and physical activity. (fda.gov)
• FDA labeling notes common GLP-1 side effects can include nausea, diarrhea, vomiting, constipation, abdominal discomfort, fatigue, reflux, and hair loss. (fda.gov)
• Research continues to support self-regulation, self-efficacy, and support as key ingredients in lasting weight loss. (pubmed.ncbi.nlm.nih.gov)
• Maintenance strategies are increasingly the focus of obesity medicine, not just initial weight loss. (pubmed.ncbi.nlm.nih.gov)
• If a trend promises “permanent” results with no maintenance, it deserves skepticism. (pubmed.ncbi.nlm.nih.gov)

5) By The Numbers

Recurrent weight gain prevention ranked highest for lifestyle interventions in the recent systematic review, while semaglutide supported continued loss during use but was followed by rebound after stopping. (pubmed.ncbi.nlm.nih.gov)

Why you should care: The most important question isn’t “How fast can I lose it?” It’s “What plan can I keep doing when life gets messy?” (pubmed.ncbi.nlm.nih.gov)

6) Ask The Community

What has helped you more this month: a medication, a habit change, or a support system—and what made the biggest difference?

7) Tomorrow’s Preview

Tomorrow we’re digging into expert guidance on plateau-proofing your plan, including what to do when progress slows, appetite returns, or motivation dips.

New GLP-1 data, real-world weight regain, and what sustainable loss actually looks like

Preview: Today’s evidence says the medication story is bigger than the weekly shot: access, adherence, and habits still matter.

Today’s News Headlines

The most important weight-loss story today isn’t a “miracle” headline—it’s a reminder that GLP-1s can help, but
they’re not the whole solution. New research in February 2026 found that weight regain after stopping GLP-1 therapy
is common, reinforcing what obesity specialists have been saying for years: obesity is chronic, and long-term planning
matters.
(pubmed.ncbi.nlm.nih.gov)

Today’s Top Stories

1) Stopping GLP-1s often means some weight comes back

A retrospective cohort study published in February 2026 found that people who discontinued GLP-1 medications commonly
regained weight afterward, highlighting the chronic nature of obesity treatment. The findings don’t mean the
medications “don’t work”—they mean they work best as part of a longer-term strategy that includes nutrition,
activity, sleep, and follow-up care.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: Readers should think of GLP-1s as treatment, not a temporary trick.

2) Supply and access remain a real part of the weight-loss conversation

FDA materials still reflect the broader reality that semaglutide products have been tied to ongoing drug-shortage and
access issues, and coverage remains uneven. In the real world, many patients still face cost barriers, prior
authorization, or limited insurance coverage for obesity medications.
(fda.gov)

Why it matters: The best medication in the world doesn’t help if people can’t access it consistently.
(statnews.com)

3) Newer reviews keep confirming the tradeoff: strong efficacy, common GI side effects

A 2026 systematic review found GLP-1 receptor agonists remain effective for obesity management, but gastrointestinal side
effects are common, including nausea, vomiting, and diarrhea. That’s one reason expert-guided dose titration and
individualized counseling matter so much.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: If side effects aren’t managed well, people stop treatment too soon.

Deep Dive: Medication Monday

GLP-1s are powerful—but they’re not magic

Wegovy and Zepbound are FDA-approved for chronic weight management, and their labeling makes clear they’re meant to be
used with reduced-calorie eating and increased physical activity. They can produce meaningful weight loss, but they also
come with important safety considerations, including GI effects and other listed warnings and precautions.
(fda.gov)

What readers should remember:

• Side effects are common, especially early on. Nausea, vomiting, diarrhea, and constipation are among the most reported issues.
  (pubmed.ncbi.nlm.nih.gov)
• Stopping abruptly can backfire. Recent evidence suggests weight regain after discontinuation is a real risk.
  (pubmed.ncbi.nlm.nih.gov)
• Lifestyle still matters on medication. Protein intake, resistance training, sleep, and regular follow-up help preserve muscle and improve long-term outcomes.
  This is an evidence-based inference from the medication’s chronic-use framing and real-world digital coaching data showing better outcomes with engagement.
  (fda.gov)

Compassionate takeaway: If you’re on a GLP-1 and struggling, that does not mean you’re failing. It may mean your dose, food pattern, hydration, or support plan needs adjustment.
(pubmed.ncbi.nlm.nih.gov)

Quick Hits

• FDA documents continue to reinforce approved uses for semaglutide and tirzepatide products in chronic weight management.
  (fda.gov)
• Stat reported recent GLP-1 pricing pressure, with major manufacturers cutting net prices in some channels.
  (statnews.com)
• Real-world data after bariatric surgery suggest GLP-1s may help some people with weight regain or insufficient loss after surgery.
  (pubmed.ncbi.nlm.nih.gov)
• Digital support appears to matter. In a service evaluation study, engaged GLP-1 users lost more weight than nonengaged users at 3 months.
  (pubmed.ncbi.nlm.nih.gov)
• Compounded GLP-1 products remain a caution zone; FDA and medical groups continue to emphasize approved products and careful prescribing.
  (fda.gov)
• A reminder for myth-checking: More weight loss is not always better if it comes with muscle loss, under-eating, or treatment fatigue. That’s why sustainable pacing matters.
  (pubmed.ncbi.nlm.nih.gov)

By The Numbers

9% vs. 5.9% — In one digital-engagement study of people using GLP-1 or GLP-1/GIP therapy, participants
who actively engaged with support lost about 9% of body weight at 3 months, compared with 5.9% among less-engaged users.
(pubmed.ncbi.nlm.nih.gov)

What it means: Medication works better when people also get coaching, accountability, and behavior support.
(pubmed.ncbi.nlm.nih.gov)

Why readers should care: The strongest results usually come from combining tools, not relying on one.
(pubmed.ncbi.nlm.nih.gov)

Ask The Community

What’s been the most helpful part of your weight-loss journey so far: medication, habit changes, community support, or something else entirely?

Tomorrow’s Preview

Tomorrow we’ll break down one recent obesity study in plain English, separating what the research really says from the headlines.

Weight Loss Daily

Saturday, March 21, 2026

Subject line: Weekend Reset: What Actually Helps Weight Loss Stick Long-Term

Preview text: New research, GLP-1 updates, and one mindset shift that can make maintenance feel more doable.

Today’s News Headlines

The weight-loss story that matters most right now isn’t a “miracle” diet—it’s sustainability.
Recent clinical evidence continues to show that GLP-1 medications can deliver meaningful weight loss,
but long-term success still depends on habits, support, and realistic expectations.
(pubmed.ncbi.nlm.nih.gov)

Today’s Top Stories

1) Higher-dose semaglutide may help some people lose more weight

A phase 3b trial of once-weekly semaglutide 7.2 mg in adults with obesity found greater weight loss than the
standard 2.4 mg dose, with participants also receiving lifestyle intervention. This does not
mean everyone should escalate dose—side effects, individual goals, and prescribing guidance still matter.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: It suggests future obesity treatment may become even more personalized, especially for people who plateau on standard doses.
(pubmed.ncbi.nlm.nih.gov)

Source: (pubmed.ncbi.nlm.nih.gov)

2) FDA is still warning about unsafe GLP-1 compounded and imported ingredients

The FDA said it launched a “green list” to help protect consumers from illegal imported GLP-1 active ingredients and
reiterated concerns about compounded semaglutide and tirzepatide, including dosing errors and unapproved salt forms.
That’s a reminder to verify exactly what medication you’re taking and where it came from.
(fda.gov)

Why it matters: Patients trying to save money can be exposed to serious safety risks if they use unverified sources.
(fda.gov)

Source: (fda.gov)

3) Real-world obesity clinic data show persistence still matters

A retrospective academic-clinic study found that, in routine care, semaglutide and tirzepatide use was common and outcomes
varied with titration and persistence. The practical takeaway: the “best” medication only works if people can stay on it,
tolerate it, and access it consistently.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: This is the gap between clinical-trial results and real life—coverage, side effects, and follow-up drive outcomes.
(pubmed.ncbi.nlm.nih.gov)

Source: (pubmed.ncbi.nlm.nih.gov)

Deep Dive: Weekend Edition — Mindset & Strategy

Why “maintenance mode” deserves more respect

A lot of weight-loss plans fail not because people lack willpower, but because they’re built like a sprint instead of a system.
Behavioral research and clinical experience both point to the same theme: smaller routines repeated consistently—meal planning,
protein-forward breakfasts, walking after meals, strength training, and sleep protection—are more durable than all-or-nothing restriction.
(pubmed.ncbi.nlm.nih.gov)

Three habits that can help this week:

• Use a “good enough” meal template: protein + fiber + color + a satisfying carb.
• Set a minimum movement target: even 10–15 minutes after meals counts.
• Plan for friction: keep one easy lunch, one easy dinner, and one backup snack ready.

Myth-bust: You do not need to eat perfectly to lose weight or keep it off. Research consistently supports
gradual, sustainable change over extreme rules that are hard to maintain.
(pubmed.ncbi.nlm.nih.gov)

Quick Hits

• The FDA’s GLP-1 supply and compounding guidance remains a major issue for patients trying to avoid interruptions.
  (fda.gov)
• Semaglutide continues to be studied in higher doses and different populations, reinforcing how active obesity medicine remains.
  (pubmed.ncbi.nlm.nih.gov)
• Real-world clinic data are increasingly important because they reflect access barriers, side effects, and adherence.
  (pubmed.ncbi.nlm.nih.gov)
• Cochrane’s recent review found semaglutide reduces body weight versus placebo and increases the chance of achieving clinically meaningful loss.
  (pubmed.ncbi.nlm.nih.gov)
• If you’re comparing options, remember that medications and lifestyle change are not rivals—they’re often complementary.
  (fda.gov)

By The Numbers

10.73% — That’s the mean percentage body-weight reduction reported in a recent Cochrane review of semaglutide for adults living with obesity versus placebo in the medium term.
(pubmed.ncbi.nlm.nih.gov)

What it means: For many patients, GLP-1 therapy can produce clinically meaningful weight loss, not just a small scale change.
(pubmed.ncbi.nlm.nih.gov)

Why you should care: It helps set realistic expectations—these medications are powerful, but they’re tools, not magic.
(pubmed.ncbi.nlm.nih.gov)

Ask The Community

What’s the one habit that has helped you most with consistency: meal prep, walking, strength training, sleep, or something else?

Tomorrow’s Preview

Tomorrow we’ll turn to Science Simplified and break down a new obesity study in plain English—what it found, what it didn’t, and what you can actually do with the results.

GLP-1 Crackdown, Semaglutide Science, and the Truth About “Easy” Weight Loss

Preview: Today’s biggest weight-loss story isn’t a miracle hack—it’s the growing push for safer, more transparent obesity care.

Today’s News Headlines

The weight-loss conversation is shifting fast: the FDA just warned 30 telehealth companies over misleading marketing of compounded GLP-1 products, putting safety and transparency back in the spotlight. At the same time, fresh research continues to reinforce a more nuanced message: medications can help, but preserving muscle, building habits, and using them appropriately still matter just as much.
(fda.gov)

Today’s Top Stories

FDA cracks down on compounded GLP-1 marketing

The FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims that imply they are the same as FDA-approved medicines. The agency also reiterated that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.

Why it matters: Patients deserve access solutions that are honest, not hype-driven—and this is a reminder to verify where your medication is coming from.
(fda.gov)

Semaglutide study adds to the body-composition conversation

A 2026 study of semaglutide 2.4 mg found substantial weight loss along with reductions in fat mass and visceral fat, while reporting preserved lean mass and improved muscle function over 12 months. That’s encouraging, but it doesn’t mean muscle loss is never a concern—other reviews still note that a meaningful share of weight lost on GLP-1 therapy can come from lean tissue.

Why it matters: If you’re using a GLP-1, protein, resistance training, and adequate sleep are not “extras”; they’re part of making the treatment work better.
(pubmed.ncbi.nlm.nih.gov)

GLP-1 access gets cheaper—but not simple

STAT reports that Novo Nordisk and Lilly have been cutting net prices for popular GLP-1 weight-loss drugs through insurer and consumer discounts, including recent deals tied to the Trump administration. Lower prices could improve access, but coverage, formulary rules, and prior authorization still determine whether patients actually feel that relief at the pharmacy counter.

Why it matters: A lower sticker price does not automatically mean lower out-of-pocket cost, so insurance navigation still matters.
(statnews.com)

Oral GLP-1s are advancing, but they’re not a magic shortcut

STAT noted that oral GLP-1 development has been a long road, and injectable GLP-1s remain the standard for obesity treatment at present. That matters because “pill instead of shot” headlines can create unrealistic expectations before the evidence, dosing, and tolerability are fully established.

Why it matters: Convenience is great, but long-term outcomes and safety still come first.
(statnews.com)

Deep Dive: Expert Insights

Q: “If I’m on a GLP-1, what should I focus on besides the scale?”

A: The best answer is surprisingly unglamorous: protein, strength training, hydration, and consistency. Evidence from recent reviews suggests GLP-1s are highly effective for weight loss, but some of that loss can include lean mass, which is one reason clinicians often recommend resistance training and adequate dietary protein during treatment.
(pubmed.ncbi.nlm.nih.gov)

Q: “Should I worry about compounded semaglutide or tirzepatide?”

A: Be cautious. The FDA has warned about illegal marketing, dosing errors, unapproved salt forms, and products that may not match FDA-approved versions. If cost or availability is forcing you toward compounded options, talk with a licensed clinician about the specific source, formulation, and risks before starting.
(fda.gov)

Q: “What’s the most practical habit if I’m not using medication?”

A: Build a boring, repeatable routine: eat protein at breakfast, plan one high-fiber meal a day, and walk after meals when possible. The point is not perfection; it’s creating enough structure that your environment stops making every choice feel like a negotiation. This is also where sustainability beats short-term restriction.
(pubmed.ncbi.nlm.nih.gov)

Quick Hits

• The FDA says Wegovy now also carries a cardiovascular risk-reduction indication in adults with obesity or overweight and established cardiovascular disease.
  (fda.gov)
• Zepbound remains FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition.
  (fda.gov)
• Zepbound is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity, making it one of the most multi-purpose obesity medicines in the market.
  (fda.gov)
• PubMed’s latest obesity literature continues to emphasize body composition, not just pounds lost, as a key issue in treatment planning.
  (pubmed.ncbi.nlm.nih.gov)
• Reddit’s r/loseit remains full of the same theme that works in real life: smaller, repeatable habits beat dramatic “all-or-nothing” pushes.
  (reddit.com)
• The FDA is continuing to crack down on unapproved GLP-1 products and misleading claims around them.
  (fda.gov)

By The Numbers

5% to 10% is the amount of body weight the FDA notes can improve cardiovascular risk in adults with obesity or overweight. That number matters because it reframes progress: you do not need a dramatic transformation for meaningful health benefits. Small-to-moderate losses can still change blood pressure, blood sugar, and long-term risk.
(fda.gov)

Ask The Community

What has helped you most this month: a medication, a habit change, meal planning, or simply giving yourself more grace? Reply and share what’s actually been sustainable for you.

Tomorrow’s Preview

Tomorrow we’re breaking down a recent obesity study into plain English and translating it into 3 practical takeaways you can use right away.

Daily Cut: Metabolic Health & Sustainable Weight Loss (Wed, March 18, 2026)

1) Today’s News Headlines

• Medicare is moving—carefully—toward broader access to FDA-approved GLP-1 obesity meds with a short-term 2026 “bridge” program that could reshape affordability for millions.
• Meanwhile, real-world data continue to show tirzepatide users tend to lose more weight than semaglutide users, reinforcing that “which drug” (and whether you can stay on it) matters as much as “are you on one.”
  (JAMA Network)

2) Today’s Top Stories (past 24 hours)

Medicare’s 2026 GLP-1 “Bridge” Program: What’s known so far

CMS will run a temporary program (“Medicare GLP-1 Bridge”) from July 1–December 31, 2026 that covers
Wegovy (semaglutide) and Zepbound (tirzepatide) for eligible beneficiaries for a
$50 monthly copay, operating outside the standard Part D benefit. Eligibility (per KFF’s summary of CMS details)
is tied to BMI ≥35, or BMI ≥27 plus additional clinical criteria, with a centralized CMS prior-authorization process.
(KFF)

Why it matters: If you’ve been locked out by “weight-loss exclusion” rules, this is one of the first concrete federal pathways to access—though it’s time-limited and still comes with cost and paperwork.
(KFF)

Source: KFF Quick Take (Mar 9, 2026)
(KFF)

Real-world results: Tirzepatide vs semaglutide—who loses more?

A large U.S. clinical analysis in JAMA Internal Medicine found that adults with overweight/obesity who started
tirzepatide were more likely to achieve ≥5%, ≥10%, and ≥15% weight loss than those starting
semaglutide, with larger average reductions at 3, 6, and 12 months. This is observational (not randomized),
so it can’t prove causation—but it’s highly relevant to “what happens in real clinics,” including discontinuation and switching.
(JAMA Network)

Why it matters: If your progress stalls (or side effects limit dosing), your clinician may discuss switching options—this evidence helps inform that conversation.
(JAMA Network)

Source: JAMA Internal Medicine
(JAMA Network)

Coverage reality check: Medicaid tightening (state-by-state)

Some Medicaid plans have become more restrictive on GLP-1s specifically labeled for weight loss. For example, Priority Health (Michigan Medicaid) announced tighter criteria effective
Jan 1, 2026 for Saxenda, Wegovy, and Zepbound, while noting diabetes-indicated GLP-1s (e.g., Ozempic/Mounjaro) were not changing.
(Priority Health)

Why it matters: “Access” isn’t one story—it’s many. Your state and plan rules can change quickly, so annual re-checks (and PA strategy) matter.
(Priority Health)

Source: Priority Health provider notice
(Priority Health)

3) Deep Dive (Wednesday: Community Voices)

“I asked HR for GLP-1 coverage—here’s what happened.” (Reddit snapshot)

A post shared today in r/GLP1ResearchTalk describes a reader whose plan explicitly excludes weight-loss medications; they’ve been paying out of pocket for months and finally asked HR directly about adding GLP-1 coverage.
The discussion that followed was blunt but useful: coverage often comes down to what the employer asks the broker for, what the insurer will offer, and what the employer will pay—meaning “no” isn’t always permanent, but it’s rarely personal.
(Reddit)

Actionable lessons (even if you don’t use GLP-1s):

1. Ask for the exact exclusion language (pharmacy benefit vs medical benefit; obesity indication vs diabetes indication). Bring it to your prescriber so they can document correctly and avoid mismatched coding.
2. Build a “value case,” not a vibe: cite cardiometabolic risks, work productivity, and long-term cost offsets; ask HR what documentation they need for next plan year evaluation.
3. Have a Plan B that still moves you forward: if access changes, you want a lifestyle “floor” (protein + fiber + steps + sleep) that keeps weight regain risk lower.

Note: Reddit is not medical advice; treat it as community insight and advocacy tactics, not clinical guidance.
(Reddit)

4) Quick Hits

• Medicare detail that surprised many: the Bridge program’s $50 copay won’t count toward Part D’s deductible or out-of-pocket cap because it operates outside Part D. (KFF)
• Another catch: people using GLP-1s for other covered indications (e.g., diabetes) may still pay their plan’s cost-sharing—even if that’s more than $50.
  (KFF)
• CMS says the longer-term BALANCE model is voluntary for plans/states/manufacturers and is designed to pair meds with evidence-based lifestyle supports.
  (CMS.gov)
• If you’re deciding between meds, remember: observational data can guide questions, but it can’t guarantee your personal outcome (side effects, dosing, adherence, and comorbidities change the picture).
  (JAMA Network)
• If you lost access in 2026, don’t assume it’s “the insurer” only—employer plan design is often the deciding lever.
  (Reddit)

5) By The Numbers

$50/month: the copayment CMS set for the Medicare GLP-1 Bridge program covering Wegovy and Zepbound for eligible beneficiaries from
July 1–Dec 31, 2026.
(KFF)

What it means: This is a rare, explicit federal price point for obesity-labeled GLP-1 access—lower than typical cash-pay, but still a barrier for some (and it doesn’t count toward Part D out-of-pocket protections).
(KFF)

Why you should care: Even if you’re not on Medicare, policy pilots often influence employer coverage norms, PA requirements, and the broader access conversation.

6) Ask The Community

If your insurance stopped (or never started) covering anti-obesity meds, what’s one advocacy step you tried that actually moved the needle—HR request, appeal, PA strategy, state Medicaid exception, switching plans, or something else?

7) Tomorrow’s Preview

Expert Insights (Q&A): “What should I do if I’m losing weight on a GLP-1 but my strength, energy, or muscle mass feels like it’s dropping?”
(Protein targets, resistance training minimums, and red flags to bring to your clinician.)